Posts Tagged ‘PE’
Beth Waldron and Stephan Moll, MD write….
While much is known about blood clots and clotting disorders, there is still much being learnt. Medical information changes over time as new clinical trials, research studies and evidence-based guidelines contribute to knowledge of and treatments for blood clots and clotting disorders. Many of today’s standards of treatment are based upon what was learned from publications in the past.
Over the past year, a number of publications emerged which will influence future clinical decisions and potentially impact your care. Here is a summary of the ‘top clinically relevant publications from 2012’ and how they may affect you. Read the rest of this entry »
Stephan Moll, MD writes…
If you are considering to start therapy with the new oral “blood thinner” Xarelto (Rivaroxaban), there are a few safety nets that your local hospital and physician may want to establish to make therapy as safe as possible for you. Issues to be addressed are (a) dosing, (b) management of major bleeding, (c) interruption of therapy for surgery, dental procedures, and other procedures, and d) what to do if you missed a dose.
These issues are probably best addressed by the establishment of a treatment algorithm/guide for the entire hospital or physician practice. Read the rest of this entry »
Stephan Moll, MD writes… Another new oral blood thinner (Eliquis = apixaban) was approved by the FDA on Dec 28th, 2012 – to be used by patients with irregular heart beat (atrial fibrillation) to prevent stroke. The drug is NOT yet FDA-approved for treatment of patients with DVT or PE. Clinical trials evaluating Eliquis for this indication are still ongoing. Read the rest of this entry »
Stephan Moll, MD writes… An important study (ASPIRE trial), relevant for patients with a history of DVT or PE, was published this week (Nov 22nd, 2012) in the New England Journal of Medicine [ref 1] . It showed that aspirin is not effective in preventing further DVT or PE in patients who have had a previous unprovoked (= idiopathic) DVT or PE and who have completed standard length (often considered to be 3-6 months) of blood thinner (warfarin) therapy. However, aspirin still had some benefit – it decreased the occurence of “vascular events” (i.e. a conglomerate of heart attacks, strokes, and DVT and PE when all were grouped together). Aspirin did not lead to an increase in risk of major bleeding. Read the rest of this entry »
Stephan Moll, MD writes… Klippel-Trenaunay Syndrome (KTS) is a rare disorder people are born with. Some individuals with KTS develop blood clots in legs, arms or pelvis (deep vein thrombosis = DVT) or in the lung (pulmonary embolism = PE) Read the rest of this entry »
Stephan Moll, MD writes… An important study was published on May 23rd, 2012 in the New England Journal of Medicine [ref 1], showing that aspirin decreases the risk of recurrent clots (DVT and PE) in patients who have had a previous unprovoked (= idiopathic) clot and who have completed 6 to 18 months of blood thinner therapy. Aspirin did not lead to an apparent increase in risk of major bleeding Read the rest of this entry »
Stephan Moll, MD writes… Some patients may only have mild symptoms when diagnosed with a deep vein thrombosis (DVT) or pulmonary embolism (PE) and may feel normal again within a few days after initiation of blood thinners. Patients with more extensive clots and more pronounced symptoms may take several weeks to get back to normal Read the rest of this entry »
Stephan Moll, MD writes…
The large clinical trial comparing Xarelto (Rivaroxaban) with warfarin in the treatment of patients with newly diagnosed pulmonary embolism (PE) was published in the New England Journal of Medicine March 26th, 2012, showing that Xarelto was (a) as effective as warfarin in preventing new clots, (b) caused the same amount of overall clinically relevant bleeding, and (c) caused less major bleeding. Read the rest of this entry »
Beth Waldron, Program Director of Clot Connect writes…
The person diagnosed with a blood clot may develop depression and anxiety, particularly if the clot was extensive and life-threatening. This can be difficult to deal with. Emotional states (such as depression, anxiety, happiness and optimism) have been shown to influence health outcomes in many medical conditions. (,,) However, very little research has been done examining the psychological impact of a blood clot on a patient’s health outcome.
What is known about the psychological impact of having a blood clot?
High levels of anxiety, depression and psychological stress have been reported among patients with deep vein thrombosis-DVT or pulmonary embolism-PE (DVT and PE are referred to collectively as VTE or venous thromboembolism).(,) This may be attributed to several factors: Read the rest of this entry »
Xarelto (Rivaroxaban) was approved in Europe today (Dec 19th, 2011) for patients with acute DVT. This is good news on the path to have a blood thinner for patients with DVT available that is easier to deal with than Warfarin. Read the rest of this entry »